Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New eye scan method could unlock secrets of blurry vision disease

NCT ID NCT07347119

Knowledge-focused Sponsor: Sun Yat-sen University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will use a special type of eye scan (ultra-widefield OCTA) to measure blood vessel patterns in people with central serous chorioretinopathy (CSC), a condition that causes fluid buildup and blurry vision. Researchers aim to create a more precise way to analyze these images, moving beyond simple visual inspection. The study involves 120 adults with CSC who have not yet received treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study subjects were recruited from outpatients of the Medical Retina Department at Zhongshan Ophthalmic Center, and eligible cases meeting the study criteria were selected from the outpatient medical record system.

Ages

18 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 60 years, inclusive; * Clinical diagnosis of central serous chorioretinopathy (CSC); * Completion of fundus fluorescein angiography (FFA) and indocyanine green angiography (ICGA) examinations; * Completion of ultra-widefield optical coherence tomography angiography (UWF-OCTA) imaging; * No prior history of pharmacological or surgical treatment for CSC; * Ability and willingness to provide written informed consent. Exclusion Criteria: -Presence of other ophthalmic diseases that may affect retinal or choroidal imaging or analysis, including but not limited to: Significant refractive media opacities interfering with OCTA imaging (e.g., severe cataract, vitreous hemorrhage); * Presence of systemic diseases that may affect study outcomes or participant safety; * Pregnant or lactating women; * History of psychiatric or mental disorders that may impair compliance; * Hemorrhagic diathesis or requirement for long-term anticoagulant therapy; * History of long-term systemic medication use that may affect choroidal or retinal circulation; * Presence of severe and/or uncontrolled comorbid medical conditions, including but not limited to: Uncontrolled diabetes mellitus; Uncontrolled hypertension; Active uncontrolled infection; Chronic obstructive pulmonary disease (COPD) with dyspnea at rest; * History of intraocular surgery or intravitreal injection within the past 6 months; * High refractive error defined as: Spherical equivalent (SE) \< -6.0 diopters or \> +3.0 diopters, or Axial length (AL) \> 26.0 mm; -Any other condition that, in the opinion of the investigator, would make participation unsafe or interfere with protocol adherence.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Central serous chorioretinopathy (CSC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

central serous chorioretinopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Central serous chorioretinopathy (CSC)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Zhongshan Ophthalmic Center, Sun Yat-sen University

    Guangzhou, Guangdong, 510060, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.